Skip to content

Biogen BIIB Long-Term Debt

Long-Term Debt at other companies

Eli Lilly logo
Eli LillyLLY
$39.37B+14.1%
TG Therapeutics logo
TG TherapeuticsTGTX
$745.14M+204%
Scholar Rock logo
Scholar RockSRRK
$196.61M+295%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
$48.96M+15.3%
Organon logo
OrganonOGN
$8.55B-4.3%

Other financials

Income statement

See full
Revenue$2.7B+3.4%
Gross profit$2.0B-4.0%
Operating income$610.7M
Net income$97.5M-84.6%
EPS (diluted)$0.66-84.8%

Balance sheet

See full
Cash & equivalents$1.3B-53.4%
Total debt$7.6B+14.6%
Total equity$18.8B+6.9%
Total assets$32.1B+13.3%

Cash flow

See full
Operating cash flow$448.9M+179%
CapEx$40.9M+53.8%
Free cash flow$408.0M+204%

Valuation

See full
Market cap$30.36B+66.6%
Enterprise value$36.63B+66.1%
P/E34.4×+22.5×
P/S+1.2×

Profitability

See full
Gross margin74%-1.4pp
Operating margin22.9%
Net margin8.8%-6.5pp
FCF margin26.9%+7.1pp

Returns & leverage

See full
Return on equity4.8%-4.3pp
Debt / equity0.4×0.0×
Current ratio1.9×-0.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebt.

The official record: Biogen’s 10-Q, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biogen's long-term debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biogen's long-term debt?
Biogen (BIIB) reported long-term debt of $7.29B in Q2 2026.
How has Biogen's long-term debt changed year-over-year?
Biogen's long-term debt increased by 16.0% year-over-year, from $6.28B to $7.29B.
What is the long-term trend for Biogen's long-term debt?
Over 5 years (2020 to 2025), Biogen's long-term debt has grown at a -3.3% compound annual growth rate (CAGR), from $7.43B to $6.29B.
What does long-term debt mean?
Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.